Clinical Case Report: LECT2-Associated Adrenal Amyloidosis
暂无分享,去创建一个
M. Merino | C. Stratakis | R. Shamburek | A. Yergey | P. Backlund | E. Kebebew | P. Xekouki | S. Cologna | N. Nilubol | J. Balow | S. B. Abraham | M. Rauschecker | S. Abraham
[1] J. Bertherat,et al. WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. , 2014, Human molecular genetics.
[2] Tetsurou Yamamoto,et al. Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry. , 2013, The Journal of clinical endocrinology and metabolism.
[3] A. Yergey,et al. Quantitative Proteomic Analysis of Niemann-Pick Disease, Type C1 Cerebellum Identifies Protein Biomarkers and Provides Pathological Insight , 2012, PloS one.
[4] V. Baud,et al. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. , 2012, The Journal of clinical investigation.
[5] P. Tarugi,et al. Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum. , 2011, Advances in clinical chemistry.
[6] D. Holanda,et al. Atypical presentation of atypical amyloid. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] D. Benson,et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] A. Solomon,et al. Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies. , 2010, Kidney international.
[9] W. Young,et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. , 2008, The Journal of clinical endocrinology and metabolism.
[10] K. Scott,et al. Leukocyte chemotactic factor 2: A novel renal amyloid protein. , 2008, Kidney international.
[11] A. Goette,et al. Prevalence and pathology of amyloid in atherosclerotic arteries. , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[12] J. Bertherat,et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. , 2005, Cancer research.
[13] K. Hatakeyama,et al. Serum LECT2 level as a prognostic indicator in acute liver failure. , 2004, Transplantation proceedings.
[14] Kazuo Suzuki,et al. Identification of the leukocyte cell‐derived chemotaxin 2 as a direct target gene of β‐catenin in the liver , 2004, Hepatology.
[15] Hans Clevers,et al. Caught up in a Wnt storm: Wnt signaling in cancer. , 2003, Biochimica et biophysica acta.
[16] C. Fenoglio-Preiser,et al. beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. , 2002, Cancer research.
[17] M. Buendia,et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[18] K. Suzuki,et al. Purification and primary amino acid sequence of a novel neutrophil chemotactic factor LECT2. , 1996, Immunology letters.
[19] D. Rader,et al. In vivo metabolism of a mutant apolipoprotein, apoA-IIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. , 1992, Journal of lipid research.
[20] R. Schrier,et al. Role of aldosterone in the sodium retention of patients with nephrotic syndrome. , 1990, American journal of nephrology.
[21] J. Liepnieks,et al. Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. , 1988, Biochemical and biophysical research communications.